


NON-SEVERE COVID-19 TREATMENT

i.e. SpO2 ≥ 94% and not requiring additional oxygen

Symptoms	Therapeutics	
Asymptomatic	<ul style="list-style-type: none"> No COVID-directed therapy indicated; monitor for symptoms and changes in clinical status 	
<p>Mild symptoms i.e. sore throat, cough, headache, weakness, diarrhea, fever, etc.</p> <div data-bbox="100 813 583 1446" style="border: 1px solid black; border-radius: 15px; padding: 10px; background-color: #e0f0ff;"> <p>Related Order Sets</p> <div data-bbox="115 933 220 1063" style="border: 1px solid black; padding: 2px; margin-bottom: 5px;"> <p>PPO</p> <p>☐</p> <p>☐</p> <p>☐</p> <p>☐</p> </div> <p>Confirmed or Suspected COVID-19 Treatment - Hospital Inpatient - ADULT (click link)</p> <div data-bbox="115 1128 220 1258" style="border: 1px solid black; padding: 2px; margin-bottom: 5px;"> <p>PPO</p> <p>☐</p> <p>☐</p> <p>☐</p> <p>☐</p> </div> <p>Oral Antiviral for COVID-19 (click link)</p> <div data-bbox="115 1291 220 1421" style="border: 1px solid black; padding: 2px;"> <p>PPO</p> <p>☐</p> <p>☐</p> <p>☐</p> <p>☐</p> </div> <p>Injectable Therapies for Non-Severe COVID-19 (click link)</p> </div>	<p>Consider in those with mild respiratory symptoms (especially cough):</p> <ul style="list-style-type: none"> Budesonide dry powder inhaler (inhaled corticosteroid) <ul style="list-style-type: none"> 800 mcg inh BID x 14 days or until symptom recovery Initiate within 14 days of symptom onset Do NOT substitute with nebulers, alternative inhaled or oral/ IV corticosteroids <p>Fill out the Report and Support form (click link) to initiate assessment for additional therapies including Paxlovid (nirmatrelvir/ritonavir), remdesivir, or Evusheld (tixagevimab/cilgavimab). High-risk individuals who meet referral criteria (click link) may be prescribed therapy by a non-severe COVID-19 designated prescriber (click link). Alternatively, email referrals to COVIDTreatment@nshealth.ca or fax to 902-492-5604.</p> <ul style="list-style-type: none"> Paxlovid (nirmatrelvir/ritonavir) (oral antiviral) <ul style="list-style-type: none"> Initiate within 5 days of symptom onset for non-pregnant individuals age ≥18 Remdesivir 3-day therapy (IV antiviral) <ul style="list-style-type: none"> Initiate within 7 days of symptom onset Evusheld (tixagevimab/cilgavimab) (anti-SARS-CoV-2 monoclonal antibodies) <ul style="list-style-type: none"> Second-line therapy; initiate within 7 days of symptom onset 	<p>Thromboprophylaxis  If no separate indication for anticoagulation (e.g.: known clot, a.fib.)</p>
<p>Outpatients</p>		<p>Inpatients</p>
<ul style="list-style-type: none"> No VTE prophylaxis indicated 		<ul style="list-style-type: none"> Standard VTE prophylaxis (i.e.: dalteparin 5000 units subcut daily)